BIOS Stock Overview
A biotech company, focuses on developing clinical assets. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BioSenic S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0063 |
| 52 Week High | €0.08 |
| 52 Week Low | €0.0038 |
| Beta | -2.67 |
| 1 Month Change | 0% |
| 3 Month Change | -17.11% |
| 1 Year Change | -87.84% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOS | BE Biotechs | BE Market | |
|---|---|---|---|
| 7D | -55.9% | 1.0% | -1.5% |
| 1Y | -87.8% | 11.4% | -0.07% |
Return vs Industry: BIOS underperformed the Belgian Biotechs industry which returned 11.4% over the past year.
Return vs Market: BIOS underperformed the Belgian Market which returned -0.1% over the past year.
Price Volatility
| BIOS volatility | |
|---|---|
| BIOS Average Weekly Movement | 34.2% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in BE Market | 6.6% |
| 10% least volatile stocks in BE Market | 2.2% |
Stable Share Price: BIOS's share price has been volatile over the past 3 months compared to the Belgian market.
Volatility Over Time: BIOS's weekly volatility has increased from 21% to 34% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.biosenic.com |
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company’s investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures’ and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment.
BioSenic S.A. Fundamentals Summary
| BIOS fundamental statistics | |
|---|---|
| Market cap | €1.79m |
| Earnings (TTM) | -€7.44m |
| Revenue (TTM) | €2.87m |
0.6x
P/S Ratio-0.2x
P/E RatioIs BIOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOS income statement (TTM) | |
|---|---|
| Revenue | €2.87m |
| Cost of Revenue | €0 |
| Gross Profit | €2.87m |
| Other Expenses | €10.31m |
| Earnings | -€7.44m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.026 |
| Gross Margin | 100.00% |
| Net Profit Margin | -259.05% |
| Debt/Equity Ratio | -125.9% |
How did BIOS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 09:32 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioSenic S.A. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stephanie Lefebvre | Gilbert Dupont |